D89.831 — Cytokine release syndrome, grade 1
Is D89.831 billable?
Yes — D89.831 is billable for FY2027. D89.831 is a valid, billable ICD-10-CM code at the highest level of specificity in its branch. D89.831 may be submitted for encounters from October 1, 2026 through September 30, 2027.
D89.831 at a glance
| Code | D89.831 |
|---|---|
| Description | Cytokine release syndrome, grade 1 |
| Billable | Yes |
| Code set | ICD-10-CM FY2027 |
| Valid for encounters | October 1, 2026 – September 30, 2027 |
What Medicare edits apply to D89.831?
The Medicare Code Editor screens inpatient claims before they are grouped. These edits name D89.831 directly.
CMS will reject this code as the principal diagnosis on an inpatient claim. It describes something other than the condition chiefly responsible for the admission.
Which MS-DRGs does D89.831 group to?
D89.831 sits in MDC 16 and helps define the logic of 3 MS-DRGs (version 44, FY2027). Which one a stay actually groups to also depends on procedures and secondary diagnoses.
- 814Reticuloendothelial and Immunity Disorders with MCCmedical
- 815Reticuloendothelial and Immunity Disorders with CCmedical
- 816Reticuloendothelial and Immunity Disorders without CC/MCCmedical
How is D89.831 listed in the Alphabetic Index?
These are the routes through the Alphabetic Index that lead to D89.831. They show the wording a clinician may have documented, which often differs from the Tabular description.
- Syndrome › cytokine release › grade 1
Excludes1 — never code together — inherited from D80-D89
The conditions below can never be reported together with D89.831 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
Excludes1 — never code together — inherited from D89
The conditions below can never be reported together with D89.831 on the same claim. An Excludes1 note means the two conditions cannot occur in the same patient, so reporting both is a coding error.
Code first — inherited from D89.83
The underlying condition below must be sequenced before D89.831. D89.831 describes a manifestation and cannot be the principal or first-listed diagnosis.
Use additional code — inherited from D89.83
Report an additional code alongside D89.831 to fully describe the condition. D89.831 is sequenced first.
- code for adverse effect, if applicable, to identify immune checkpoint inhibitors and immunostimulant drugs (T45.AX5)
- code to identify associated manifestations
Excludes2 — not included here — inherited from Chapter 3
The conditions below are not part of D89.831, but a patient may have both at the same time. When documentation supports it, D89.831 and the excluded code may both be reported.
- autoimmune disease (systemic) NOS (M35.9)
- certain conditions originating in the perinatal period (P00-P96)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- human immunodeficiency virus [HIV] disease (B20)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Excludes2 — not included here — inherited from D80-D89
The conditions below are not part of D89.831, but a patient may have both at the same time. When documentation supports it, D89.831 and the excluded code may both be reported.
- human immunodeficiency virus [HIV] disease (B20)
Excludes2 — not included here — inherited from D89
The conditions below are not part of D89.831, but a patient may have both at the same time. When documentation supports it, D89.831 and the excluded code may both be reported.
- transplant failure and rejection (T86.-)
How long has D89.831 existed?
D89.831 first appears in FY2021 (FY2020 is not available, so it may have appeared then).
Derived from the official order files for FY2016–FY2026. FY2017 and FY2020 publish no order file, so those years are not covered.